title: Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.
abstract: The neutrophil-activating peptide-2 (NAP-2) is a cytokine that is generated by the proteolytic cleavage of a precursor protein and that causes neutrophil degranulation and chemotaxis. NAP-2 precursors are produced in platelets and are normally found in the circulation. We showed that NAP-2 is generated by the action of neutrophil cathepsin G on two of the precursors, the connective tissue-activating peptide-III (CTAP-III) and beta-thromboglobulin (beta-TG). However, neutrophil elastase degraded the precursors to inactive peptides. The specific binding of cathepsin G to platelets caused the platelets to secrete NAP-2, and cathepsin G bound to the platelets could still generate NAP-2 from its precursor proteins. In addition, activated neutrophils in the presence of platelets generated NAP-2 from its precursors and caused platelets to secrete NAP-2. These studies demonstrate a unique mechanism for the activation of neutrophils through the interaction of neutrophils, platelets, and NAP-2 precursors that are released either by activated platelets or are present in circulation. It is therefore possible that NAP-2 may be generated at sites where aggregations of neutrophils and platelets occur in vessels such as pulmonary capillaries in patients with the adult respiratory distress syndrome and coronary arteries in patients with evolving myocardial infarctions.
authors.affiliation: Department of Biochemistry, University of Texas Health Center, Tyler 75710.
authors.forename: A B
authors.initials: AB
authors.lastname: Cohen
authors.forename: M D
authors.initials: MD
authors.lastname: Stevens
authors.forename: E J
authors.initials: EJ
authors.lastname: Miller
authors.forename: M A
authors.initials: MA
authors.lastname: Atkinson
authors.forename: G
authors.initials: G
authors.lastname: Mullenbach
mesh_terms: D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism* / Q000502:physiology; D056649:Cathepsin G; D002403:Cathepsins / Q000494:pharmacology*; D002478:Cells, Cultured; D002918:Chymotrypsin / Q000494:pharmacology; D003470:Culture Media; D006801:Humans; D019272:Leukocyte Elastase; D016676:Macrophages, Alveolar / Q000378:metabolism; D009504:Neutrophils / Q000502:physiology; D010196:Pancreatic Elastase / Q000494:pharmacology; D010452:Peptide Biosynthesis; D010455:Peptides / Q000097:blood / Q000378:metabolism; D012697:Serine Endopeptidases; D001620:beta-Thromboglobulin / Q000378:metabolism / Q000502:physiology
chemical_list: D003470:Culture Media; C061615:PPBP protein, human; D010455:Peptides; D001620:beta-Thromboglobulin; C009862:connective tissue-activating peptide; D002403:Cathepsins; D012697:Serine Endopeptidases; D002918:Chymotrypsin; C534094:CTSG protein, human; D056649:Cathepsin G; D010196:Pancreatic Elastase; D019272:Leukocyte Elastase